Mersana Therapeutics Inc (NASDAQ:MRSN) — Market Cap & Net Worth
Market Cap & Net Worth: Mersana Therapeutics Inc (MRSN)
Mersana Therapeutics Inc (NASDAQ:MRSN) has a market capitalization of $145.36 Million ($145.36 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17774 globally and #3974 in its home market, demonstrating a -0.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mersana Therapeutics Inc's stock price $29.08 by its total outstanding shares 4998750 (5.00 Million). Analyse MRSN cash generation efficiency to see how efficiently the company converts income to cash.
Mersana Therapeutics Inc Market Cap History: 2017 to 2026
Mersana Therapeutics Inc's market capitalization history from 2017 to 2026. Data shows growth from $82.13 Million to $145.36 Million (8.95% CAGR).
Index Memberships
Mersana Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #491 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1736 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.01% | #235 of 263 |
Weight: Mersana Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mersana Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mersana Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.18x
Mersana Therapeutics Inc's market cap is 0.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $82.13 Million | $17.55 Million | -$38.71 Million | 4.68x | N/A |
| 2018 | $20.39 Million | $10.59 Million | -$64.26 Million | 1.93x | N/A |
| 2019 | $28.64 Million | $42.12 Million | -$28.21 Million | 0.68x | N/A |
| 2020 | $133.02 Million | $828.00K | -$88.05 Million | 160.65x | N/A |
| 2021 | $31.09 Million | $43.00K | -$170.06 Million | 723.08x | N/A |
| 2022 | $29.29 Million | $26.58 Million | -$204.21 Million | 1.10x | N/A |
| 2023 | $11.60 Million | $36.85 Million | -$171.67 Million | 0.31x | N/A |
| 2024 | $7.15 Million | $40.50 Million | -$69.19 Million | 0.18x | N/A |
Competitor Companies of MRSN by Market Capitalization
Companies near Mersana Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Mersana Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mersana Therapeutics Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Mersana Therapeutics Inc's market cap moved from $82.13 Million to $ 145.36 Million, with a yearly change of 8.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $145.36 Million | +0.52% |
| 2025 | $144.61 Million | +1923.08% |
| 2024 | $7.15 Million | -38.36% |
| 2023 | $11.60 Million | -60.41% |
| 2022 | $29.29 Million | -5.79% |
| 2021 | $31.09 Million | -76.63% |
| 2020 | $133.02 Million | +364.40% |
| 2019 | $28.64 Million | +40.44% |
| 2018 | $20.39 Million | -75.17% |
| 2017 | $82.13 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Mersana Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $145.36 Million USD |
| MoneyControl | $145.36 Million USD |
| MarketWatch | $145.36 Million USD |
| marketcap.company | $145.36 Million USD |
| Reuters | $145.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more